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The rise and fall of the "atypical" neuroleptics: a case study
in how the pharmaceutical industry hypes its products.
When the atypical antipsychotics were introduced into the
market in the early 1990s (most notably risperidone and
olanzapine), they were presented to the public as "break-
through medications" that were both more effective and
safer than the standard neuroleptics (like chlorpromazine
and haloperidol). Now we know that the atypicals are no
more effective than the older drugs, and are perhaps even
more problematic, in terms of their side effects. This pres-
entation will look at how the pharmaceutical companies
created the initial story of "breakthrough" medications,
even though the clinical trial data they submitted to the
FDA in the early 1990s revealed, in fact, that the drugs
were no more effective than the older ones and caused a
wide range of troubling side effects.
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